Clinical trials: Stage III Non-Small Cell Lung Cancer AJCC v7
Non-Small-Cell-Lung Cancer
Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC
The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal…
- Trial name
- CHER@NOS (NCT00463515)
- Testing
- carboplatin/gemcitabine, cisplatin/radiation therapy
- Where
- 3 sites in Belgium
- Volunteers
- 77 people
- Sponsor
- University Hospital, Antwerp
Non-Small Cell Lung Cancer
A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III NSCLC in separate cohorts of locally advanced and…
- Trial name
- NCT00787852
- Testing
- Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47, Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Brown University
Non-small Cell Lung Cancer
Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety of accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) concurrent with chemotherapy for patients with unresectable stage III non-small…
- Trial name
- NCT02720614
- Testing
- Hypofractionated radiation/chemotherapy
- Volunteers
- 12 people
- Sponsor
- LIN QIANG
Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07361497
- Testing
- Pumitamig, Durvalumab
- Where
- 260 sites in United States, Argentina and 30 more
- Volunteers
- 850 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00698815
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Where
- 129 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7
Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of trametinib when given together with combination chemotherapy and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be…
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01912625
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Image Guided Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed Grade 2 and higher ILD and of disease progression in patients with…
- Trial name
- iDETECT (NCT04884269)
- Where
- 27 sites in Japan
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Stage III Non-small Cell Lung Cancer
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and…
- Trial name
- NCT01102231
- Testing
- Chemotherapy, ERBITUX, Radiotherapy
- Where
- 38 sites in France
- Volunteers
- 106 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of 6,8-bis(benzylthio)octanoic acid (CPI-613) when given together with docetaxel and to see how well they work in treating patients with stage IIIB or IV non-small cell…
- Trial name
- NCT03370159
- Testing
- 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and the best dose of hypofractionated radiation therapy when given together with chemotherapy in treating patients with stage III non-small cell lung cancer that cannot be removed by…
- Trial name
- NCT01486602
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer (Stage III)
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
This study is a phase 2 open-label, single-center clinical study to evaluate the efficacy and safety SKB264 in combination with toripalimab in patients with unresectable stage III non-small cell lung cancer
- Trial name
- NCT06706219
- Testing
- Sacituzumab tirumotecan plus toripalimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
- Trial name
- NCT04762030
- Testing
- Durvalumab Anlotinib Carboplatin Nab-paclitaxel
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00589056
- Testing
- cisplatin, etoposide, nelfinavir mesylate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography, using the drug fluorine F18-EF5 to find oxygen and fludeoxyglucose F18 to find sugar in tumor cells may help in planning treatment for patients with…
- Trial name
- NCT01017133
- Testing
- fludeoxyglucose F 18, Fluorine F 18 EF5, Positron emission tomography
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033553
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 74 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC
In patients with locally advanced stage III non-small cell lung cancer, the probability of local control remains low (about 17% at 1 year). Concomitant radio-chemotherapy is the standard treatment.
- Trial name
- RTEP7 (NCT02473133)
- Testing
- Personalized dose redistribution, No personalized dose redistribution
- Where
- France
- Volunteers
- 158 people
- Sponsor
- Centre Henri Becquerel
Lung Cancer
SWOG-9416: Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00002642
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- SWOG Cancer Research Network
Stage III Non-small-cell Lung Cancer
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following…
- Trial name
- NCT04085250
- Testing
- Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Carcinoma
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or…
- Trial name
- NCT00234468
- Testing
- Iressa (Gefitinib)
- Where
- 32 sites in Italy
- Volunteers
- 490 people
- Sponsor
- AstraZeneca